Terazosin transdermal device and methods

US8496960B2 · kind B2 · utility

Assignee

• PURDUE PHARMA L.P. · US

Inventors

• Lino Tavares · Kinnelon, US
• Ihor Shevchuk · Yonkers, US
• Mark Alfonso · Easton, US
• Geraldine Marcenyac · Norwalk, US
• Kirti H. Valia · Plainsboro, US

Key dates

• Filing date: Oct 23, 2002
• Grant date: Jul 30, 2013
• Expiry date: Oct 20, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/517
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.